Trade names normally aren’t established and trademarked until after FDA preliminary approval of a drug.  Looks like our friends at Onyx are pretty confident that the FDA will step-up and quickly approve carfilzomib for relapsed/refractory myeloma patients.

When perifosine failed to extend overall survival (OS) in patients with metastasized colorectal cancer recently in a Stage 3 trial, company officials and financial analysts speculated that plans to start a stage 3 multiple myeloma theory might be scrapped:

Did you happen to read the comment from Terry yesterday following my post slamming skeletal surveys?  Just in case you missed it…

I have already heard from several fellow myeloma patients that are willing to share their stories after reading Friday’s post:

Multiple myeloma researchers have spent the last decade trying to determine which patients are high risk and less likely to respond favorably to treatment.

While we were busy being inspired–and reading nutritional tips to help us control our myeloma–there was a lot going on with the new myeloma therapies and the FDA.

Patients and caregivers were “all abuzz” last week over the new ImMucin anti-cancer vaccine.  I even wrote two posts about it:

Here is some follow-up on a more well tested anti-myeloma antibody, Elotuzumab–the kind of therapy you will find featured in my new myeloma therapies book.

Yesterday I shared the exciting–if possibly a bit premature–news about the experimental immunotherapy drug, ImMucin.

My inbox was burning-up with emails from readers who had just read about ImMucin, a new anti-cancer vaccine that is expected to work well against a number of different cancers.

Most of you probably know that I have been working on several new books about multiple myeloma. 

One more review of last December’s ASH in San Diego.

A few days back I ran a post about how improvements in the way allogeneic transplants are administered may help reduce the number and severity of side-effects:

Monday I shared the disappointing news about how the promising anti-myeloma drug, perifosine, might not ever make it to market.

Wow!  Talk about a sudden change of fortune. I just posted a link to a positive financial report from one of the companies which was set to manufacture perifosine last week:

The Myeloma Beacon’s Virginia Li wrote an interesting report late last week, highlighting how “more is not necessarily better” when it comes to myeloma therapy.

Happy Saturday!  I thought this might be a good day to group together and share several different multiple myeloma-related odds and ends…

Cancer Network is running a series I unofficially like to call “Everything you ever wanted to know about proteasome inhibitors but were afraid to ask.”

Clinical trials.  In theory and on paper, participating makes all the sense in the world.  Access to the latest and greatest new anti-myeloma meds and free medical care from the best in the field top the list of positives.

Yesterday I re-visited the topic of a new anti-myeloma therapy Mayo Clinic researchers are investigating.